Business Wire

Laser System Partnership Sets Sights on Ending Toll Road Delays

Share

A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics.

Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions.

Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.

Cepton and MechaSpin’s solution addresses such challenges by eliminating the need for physical infrastructure while providing accurate data, such as vehicle velocity, size and axle count, in a format that can be integrated with other sensor, data capture and billing systems. At the same time, the hardware is designed for aerial installation and contains minimal moving parts, reducing the likelihood of failure.

Neil Huntingdon, Cepton’s VP of Business Development, said: “Our partnership with MechaSpin is founded on both businesses’ deep understanding of the unique and powerful capabilities of lidar, especially when it is teamed with problem solving software solutions.

“We believe that this partnership will bring major innovations to the tolling industry. Our Sora-P60 lidar delivers an unrivalled scan speed at 380Hz, making it possible to profile vehicles as they pass at highway speeds. Our partnership with MechaSpin will allow for faster, more accurate and lower cost management of our transport infrastructure as the number of vehicles continues to grow globally.”

Danny Kent, PhD, MechaSpin’s President, added: “The tolling industry lacks an integrated end-to-end solution for deploying 3D lidar for vehicle classification and tracking. MechaSpin and Cepton have partnered to deliver a solution for this need. Cepton's lidar technology coupled with MechaSpin's MSx Processing Engine offers a robust solution for tolling, intermodal and other transportation industry applications.”

Cepton will be showcasing its state-of-the-art lidar solutions at the 26th ITS World Congress in Singapore from October 21 to October 25, 2019. Please visit Cepton’s booth (B04) for more information or to arrange a live demo.

Founded in 2016 by Dr. Jun Pei and Dr. Mark McCord, Cepton is the only company in the industry to ship high-performance and low-cost lidar sensors directly to customers.

Lidar technology is not new, however its usage across industries is growing thanks to its power efficient, environmentally agnostic qualities. Like bats, which use sound waves during echolocation to measure distances and determine the location of an object, lidar utilises light waves from a laser to send a pulse of light and measure the amount of time it takes to reflect back from objects, making it possible to measure the distance between them. Since the speed of light is constant, distance can be easily calculated by measuring the time it takes for the beam to return.

Lidar systems use these pulses to create three-dimensional point clouds of their surrounding area, providing cars and other smart machines with highly accurate perception data to autonomously navigate.

Cepton's Micro Motion Technology (MMT™) is unique to the industry. Unlike traditional beam-steering technologies, such as spinning lidar and micro-electronical mechanical systems (MEMS), Cepton’s MMT architecture enables a mirrorless, frictionless and rotation-free system to increase the durability, reliability and manufacturability of the product, while delivering industry-leading range and resolution for highly accurate 3D sensing.

For more information about Cepton Technologies Inc., visit www.cepton.com

For more information about MechaSpin visit www.mechaspin.com

About Cepton Technologies, Inc.

Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.

Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.

Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines.

For more information, visit: http://www.cepton.com/.

Cepton is headquartered in San Jose, California, USA.

It also has offices in Germany, Canada and UK.

About MechaSpin

MechaSpin is an experienced Systems Integrator and Solution Provider dedicated to using lidar technology to make the world safer, more efficient and more productive. MechaSpin’s MSx Processing Engine provides advanced signal processing and machine learning algorithms for 3D lidar data.

Founded in 2010, MechaSpin is led by engineers that started their careers as participants in the DARPA Grand Challenges, fielding lidar technology for autonomous robotic vehicles. MechaSpin’s team is focused on bringing sensors, algorithms and technologies from the self-driving car industry into industrial markets such as material handling, tolling, port and terminal, intermodal, and more.

For more information, visit: http://www.mechaspin.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Faithy Li, Cepton Technologies: media@cepton.com
Dyan Owen, Weber Shandwick:,+ 44 141 343 3254 / +44 7738 086 818, dowen@webershandwick.com
Steven Flanagan, Weber Shandwick: +44 141 343 3250, sflanagan@webershandwick.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye